Similar companies
Income Statement (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Revenue | 1.21B | 4.5% |
| Gross Profit | 731M | 6.2% |
| Cost of Revenue | 478M | 2% |
| Operating expense | 489M | 2.7% |
| Net Income | 284M | 57.8% |
| EBITDA | 421M | 36.2% |
Balance Sheet (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 7.5B | 2.4% |
| Total Liabilities | 4.77B | 0.4% |
| Total Equity | 2.73B | 5.9% |
| Shares Outstanding | 407M | 0.2% |
Cash Flow (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | 660M | 117.8% |
| Cash from investing | 193M | 403.1% |
| Cash from financing | -175M | 10194.1% |
EPS
Financial Highlights for Dexcom in Q3 '25
Dexcom reported a revenue of 1.21B, which is a 4.5% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 731M, marking a 6.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 478M, a 2% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 489M, showing a 2.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 284M, showing a 57.8% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 421M, showing a 36.2% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Dexcom with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
